Future Directions in Mucormycosis Research

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2012 Jan 17

PMID 22247450

Citations 20

Authors

Dimitrios P Kontoyiannis

Russell E Lewis

Oliver Lortholary

Oliver Lotholary

Brad Spellberg

Georgios Petrikkos

Emmanuel Roilides

Emmanuel Roillides

Ashraf Ibrahim

Thomas J Walsh

Affiliations

Soon will be listed here.

Abstract

Mucormycosis has emerged as an important opportunistic infection, especially in severely immunosuppressed hosts. The evolving epidemiology, immunopathogenesis, molecular virulence studies, early diagnosis, and pitfalls in designing clinical studies of mucormycosis are discussed in this article.

Citing Articles

The Fatal Course of Pulmonary Mucormycosis: A Case Report.

Sindhu A, Jadhav U, Ghewade B, Bhanushali J, Sarkar S, Yadav P Cureus. 2024; 16(8):e66018.

PMID: 39221410 PMC: 11366409. DOI: 10.7759/cureus.66018.

Mixed Aspergillosis and Mucormycosis Infections in Patients with COVID-19: Case Series and Literature Review.

Sasani E, Pakdel F, Khodavaisy S, Salehi M, Salami A, Sohrabi M Mycopathologia. 2024; 189(1):10.

PMID: 38231407 DOI: 10.1007/s11046-023-00808-z.

Mucormycosis in 2023: an update on pathogenesis and management.

Alqarihi A, Kontoyiannis D, Ibrahim A Front Cell Infect Microbiol. 2023; 13:1254919.

PMID: 37808914 PMC: 10552646. DOI: 10.3389/fcimb.2023.1254919.

Is the production of reactive oxygen and nitrogen species by macrophages associated with better infectious control in female mice with experimentally disseminated and pulmonary mucormycosis?.

Ribeiro Dos Santos A, Fraga-Silva T, Almeida-Donanzam D, Finatto A, Marchetti C, Andrade M PLoS One. 2022; 17(12):e0270071.

PMID: 36520787 PMC: 9754262. DOI: 10.1371/journal.pone.0270071.

A case of COVID-19-associated rhino-orbito-cerebral mucormycosis caused by with a review of the literature.

Erami M, Mirhendi H, Momen-Heravi M, Hashemi Hezaveh S, Ahsaniarani A, Sabet S Front Cell Infect Microbiol. 2022; 12:898477.

PMID: 36310874 PMC: 9615570. DOI: 10.3389/fcimb.2022.898477.

References

Ribes J, Baker D . Zygomycetes in human disease. Clin Microbiol Rev. 2001; 13(2):236-301. PMC: 100153. DOI: 10.1128/CMR.13.2.236. View

Ibrahim A, Spellberg B, Edwards Jr J . Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008; 21(6):620-5. PMC: 2773686. DOI: 10.1097/QCO.0b013e3283165fd1. View

Walsh T, Anaissie E, Denning D, Herbrecht R, Kontoyiannis D, Marr K . Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(3):327-60. DOI: 10.1086/525258. View

Chamilos G, Lewis R, Hu J, Xiao L, Zal T, Gilliet M . Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A. 2008; 105(27):9367-72. PMC: 2453716. DOI: 10.1073/pnas.0709578105. View

Roden M, Zaoutis T, Buchanan W, Knudsen T, Sarkisova T, Schaufele R . Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41(5):634-53. DOI: 10.1086/432579. View

Kontoyiannis D, Chamilos G, Hassan S, Lewis R, Albert N, Tarrand J . Increased culture recovery of Zygomycetes under physiologic temperature conditions. Am J Clin Pathol. 2007; 127(2):208-12. DOI: 10.1309/7KU5XWURYM0151YN. View

Chamilos G, Luna M, Lewis R, Bodey G, Chemaly R, Tarrand J . Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica. 2006; 91(7):986-9. View

Kontoyiannis D, Wessel V, Bodey G, Rolston K . Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000; 30(6):851-6. DOI: 10.1086/313803. View

Chang D, Burwell L, Lyon G, Pappas P, Chiller T, Wannemuehler K . Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis . Infect Control Hosp Epidemiol. 2008; 29(1):25-30. DOI: 10.1086/524324. View

10.

Ben-Ami R, Lewis R, Kontoyiannis D . Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis. 2008; 47(2):226-35. DOI: 10.1086/589290. View

11.

Kasai M, Harrington S, Francesconi A, Petraitis V, Petraitiene R, Beveridge M . Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol. 2008; 46(11):3690-702. PMC: 2576616. DOI: 10.1128/JCM.00917-08. View

12.

Kontoyiannis D . Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis. 2007; 44(8):1089-90. DOI: 10.1086/512817. View

13.

Smith W, Drew R, Perfect J . Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. Expert Rev Anti Infect Ther. 2009; 7(2):165-81. DOI: 10.1586/14787210.7.2.165. View

14.

Tarrand J, Lichterfeld M, Warraich I, Luna M, Han X, May G . Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol. 2003; 119(6):854-8. DOI: 10.1309/EXBV-YAUP-ENBM-285Y. View

15.

Sun H, Aguado J, Bonatti H, Forrest G, Gupta K, Safdar N . Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant. 2009; 9(9):2166-71. DOI: 10.1111/j.1600-6143.2009.02754.x. View

16.

Ruping M, Heinz W, Kindo A, Rickerts V, Lass-Florl C, Beisel C . Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2009; 65(2):296-302. DOI: 10.1093/jac/dkp430. View

17.

Dannaoui E, Schwarz P, Slany M, Loeffler J, Jorde A, Cuenca-Estrella M . Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection.... J Clin Microbiol. 2010; 48(6):2043-6. PMC: 2884487. DOI: 10.1128/JCM.02319-09. View

18.

Dannaoui E, Meletiadis J, Mouton J, Meis J, Verweij P . In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2002; 51(1):45-52. DOI: 10.1093/jac/dkg020. View

19.

Spellberg B, Ibrahim A, Chin-Hong P, Kontoyiannis D, Morris M, Perfect J . The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2011; 67(3):715-22. PMC: 3383100. DOI: 10.1093/jac/dkr375. View

20.

Liu M, Spellberg B, Phan Q, Fu Y, Fu Y, Lee A . The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010; 120(6):1914-24. PMC: 2877958. DOI: 10.1172/JCI42164. View